World Journal of Urology

, Volume 33, Issue 6, pp 833–839

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

Authors

    • Department of Urology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Sonia Vallet
    • Department of Medical Oncology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Boris A. Hadaschik
    • Department of Urology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Sascha Pahernik
    • Department of Urology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Stefan Duensing
    • Department of Urology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
    • Section of Molecular Urooncology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Markus Hohenfellner
    • Department of Urology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
  • Dirk Jäger
    • Department of Medical Oncology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
    • Department of Medical Oncology, National Center for Tumor Diseases (NCT)University Hospital Heidelberg
Original Article

DOI: 10.1007/s00345-014-1375-5

Cite this article as:
Höfner, T., Vallet, S., Hadaschik, B.A. et al. World J Urol (2015) 33: 833. doi:10.1007/s00345-014-1375-5

Abstract

Purpose

To report the outcome and course of disease in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel followed by abiraterone acetate in a single center.

Methods

In this retrospective observational study, we reviewed the course of disease of all applicable patients with mCRPC treated with docetaxel followed by abiraterone at our center. We analyzed progression-free survival (PFS) of docetaxel and abiraterone treatments. We further searched for predictive factors for the duration of treatment response.

Results

Median PFS between initiation of androgen deprivation therapy and the diagnosis of mCRPC was 32 months. Median PFS on docetaxel treatment was 9 months. Median PFS on abiraterone treatment was 11 months. Patients with higher Gleason scores (GS) (8–10) at initial diagnosis had a significantly longer median PFS on docetaxel as compared to patients with GS 6–7, p = 0.01. We demonstrate a significant correlation between the PFS on docetaxel and PFS on abiraterone in the post-docetaxel setting (Kendall tau r = 0.32, p = 0.019) as well as a significant negative correlation between the PSA nadir under abiraterone treatment and the time to progression under abiraterone (Kendall tau r = −0.43, p = 0.007).

Conclusions

High Gleason score appears to be predictive of duration of response to docetaxel. Interestingly, progression-free survival with abiraterone appears to be correlated with the duration of response with docetaxel, whereas PSA decline and low nadir appear to be predictive of response to abiraterone.

Keywords

Abiraterone acetateDocetaxelChemotherapyMetastatic prostate cancerSurvival

Copyright information

© Springer-Verlag Berlin Heidelberg 2014